CARLSBAD, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in a patent application derived from the “Tuschl III” patent series that is assigned to Max Planck. The allowed claims relate to human microRNA miR-21, a microRNA that is a potential target for a number of therapeutic indications. Regulus has access to the Tuschl III patent series for microRNA therapeutics through license agreements amongst Max Planck, Alnylam, and Isis.
